ABSTRACT
This was the question that motivated CFI and CIHR to undertake an interagency collaboration in evaluation that explored in depth the net economic and health benefits that resulted from their investments. This paper reviews and presents the findings from one important piece of that evaluation: a case study of publicly-supported imaging R&D involving the comingling of complimentary public expenditures by these two agencies. The case study is that of computed tomography perfusion (CTP), an imaging study that uses computed tomography (CT) to measure blood flow in organs and tissues and is most commonly used in assessing moderate to severe acute ischemic stroke.
